Oxford Immunotec Global PLC (NASDAQ:OXFD) shares saw unusually-strong trading volume on Friday . Approximately 73,278 shares were traded during trading, an increase of 4% from the previous session’s volume of 70,324 shares.The stock last traded at $8.65 and had previously closed at $8.73.

Several equities research analysts have issued reports on OXFD shares. BTIG Research reaffirmed a “buy” rating and set a $17.00 price target on shares of Oxford Immunotec Global PLC in a research note on Monday, June 27th. Zacks Investment Research cut shares of Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a research note on Wednesday, July 6th. Finally, Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Oxford Immunotec Global PLC in a research note on Sunday, June 26th.

The stock has a 50 day moving average of $8.96 and a 200-day moving average of $9.99. The stock’s market cap is $199.03 million.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last posted its quarterly earnings data on Tuesday, May 3rd. The company reported ($0.32) earnings per share for the quarter, hitting the consensus estimate of ($0.32). The company earned $17.10 million during the quarter, compared to analyst estimates of $16.96 million. During the same period in the previous year, the company earned ($0.31) EPS. The business’s revenue for the quarter was up 23.9% compared to the same quarter last year. Equities analysts predict that Oxford Immunotec Global PLC will post ($1.28) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Oxford Immunotec Global PLC stock. OppenheimerFunds Inc. increased its stake in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 0.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,068,967 shares of the company’s stock after buying an additional 5,440 shares during the period. OppenheimerFunds Inc. owned approximately 4.74% of Oxford Immunotec Global PLC worth $12,293,000 at the end of the most recent reporting period.

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.